Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone.
The discussion covered the clinical significance of achieving minimal residual disease (MRD) negativity, with Zandra correlating the depth of response to long-term outcomes. She expressed cautious optimism for the high-risk patient population, highlighting the need for extended follow-up. Safety and tolerability considerations were addressed, with Zandra acknowledging numerical imbalances in deaths and emphasizing the importance of awaiting further survival results.
ASH 2023 witnessed an exploration of the ISKIA trial guided by Zandra Klippel’s expertise. Her contributions left the audience with an understanding of potential shifts in multiple myeloma treatment.